Cholestatic Liver Disease after Rituximab and Adalimumab and the Possible Role of Cross-Reacting Antibodies to Fab 2 Fragments

• Joerg Latus ,

  Contributed equally to this work with: Joerg Latus, Reinhild Klein

  * E-mail: Joerg.latus@rbk.de

  Affiliation Department of Internal Medicine, Division of Nephrology, Robert-Bosch Hospital Stuttgart, Germany

  ⨯
• Reinhild Klein ,

  Contributed equally to this work with: Joerg Latus, Reinhild Klein

  Affiliation Department of Internal Medicine II, University Hospital Tuebingen, Germany

  ⨯
• Ina Koetter,

  Affiliation Department of Internal Medicine, Division of Nephrology, Robert-Bosch Hospital Stuttgart, Germany

  ⨯
• Matthias Schwab,

  Affiliation Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology and University Tuebingen, Stuttgart, Germany

  ⨯
• Peter Fritz,

  Affiliation Institute of Digital Medicine, Stuttgart, Germany

  ⨯
• Martin Kimmel,

  Affiliation Department of Internal Medicine, Division of Nephrology, Robert-Bosch Hospital Stuttgart, Germany

  ⨯
• M. Dominik Alscher,

  Affiliation Department of Internal Medicine, Division of Nephrology, Robert-Bosch Hospital Stuttgart, Germany

  ⨯
• Niko Braun

  Affiliation Department of Internal Medicine, Division of Nephrology, Robert-Bosch Hospital Stuttgart, Germany

  ⨯